MUNICH, Dec 19 (Reuters) - Germany's patent court on Tuesday invalidated a patent that was the basis of a patent violation lawsuit brought by CureVac against its domestic rival BioNTech, a blow to CureVac's claims for a share in billions in COVID-19 vaccine revenues. (Reporting by Joern Poltz Writing by Ludwig Burger, Editing by Rachel More)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
The $50 million purchase could turn into Nvidia's biggest investment.
This little-known software stock could soar as businesses spend more on generative artificial intelligence.
These two dividend payers have historically high yields and attractive businesses, even though there are some headwinds to deal with.
A month after a higher state minimum wage for fast-food workers went into effect, consumers picking up burgers and burritos at chains in the Golden State grapple with prices rising at a faster clip than in other states.
In addition to economic and earnings news, inflation and geopolitical worries will have roles to play.
“When she died, we were told by her attorney that we were responsible for the taxes and property insurance during the time when the life tennant lives in the home.”
The tobacco giant will soon be allowed to sell a proven product in a proven market.
The recent pullback in price is a rare opportunity for investors to add to this high-flying stock.